Proteologics' ubiquitin Target & Drug Discovery Platform offers a very broad potential. This potential has already materialized into two strategic partnerships with GSK and Teva. Currently Proteologics is engaged in three drug discovery programs in cancer therapy, in collaboration with Teva Pharmaceutical and is now building upto six more drug discovery programs in cancer therapy with GSK. As well as one independent program that is being developed by proteologics alone. These programs are each being focused on a specific and distinct drug target/ biochemical pathway in the ubiquitin system.
There is a known causative link between the ubiquitin system and many other major human diseases including many cancers, neuro-degenerative conditions (such as Alzheimer's and Parkinson's diseases), cystic fibrosis and immune disorders. Based on Proteologics' leading position in ubiquitin based target and drug discovery, additional research programs in cancer, CNS diseases and anti-viral are currently under discussion with potential corporate partners.